ChemicalBook
Chinese english Germany Korea

シルデナフィル

シルデナフィル 化学構造式
139755-83-2
CAS番号.
139755-83-2
化学名:
シルデナフィル
别名:
シルデナフィル;シルデナフィル;シルデナフィル 溶液
英語化学名:
Sildenafil
英語别名:
viagTa;Revatio;UK-92480;Sildefil;SIDANAFIL;SILDENAFIL;SiIdenafiI;sildenafll;Sildenafile;Sildenafil h
CBNumber:
CB2747316
化学式:
C22H30N6O4S
分子量:
474.58
MOL File:
139755-83-2.mol

シルデナフィル 物理性質

融点 :
187-189°C
比重(密度) :
1.39±0.1 g/cm3(Predicted)
闪点 :
9℃
貯蔵温度 :
Sealed in dry,Store in freezer, under -20°C
酸解離定数(Pka):
pKa 8.7 (Uncertain)
InChIKey:
BNRNXUUZRGQAQC-UHFFFAOYSA-N
CAS データベース:
139755-83-2(CAS DataBase Reference)
EPAの化学物質情報:
7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl- (139755-83-2)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  Xi,T,F
Rフレーズ  36/37/38-39/23/24/25-23/24/25-11
Sフレーズ  22-24/25-36-26-45-36/37-16-7
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  1
HSコード  38220090
有毒物質データの 139755-83-2(Hazardous Substances Data)
絵表示(GHS)
注意喚起語 Danger
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H225 引火性の高い液体および蒸気 引火性液体 2 危険 P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H370 臓器の障害 特定標的臓器有害性、単回暴露 1 危険 P260, P264, P270, P307+P311, P321,P405, P501
注意書き
P210 熱/火花/裸火/高温のもののような着火源から遠ざ けること。-禁煙。
P260 粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。
P280 保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。
P301+P310 飲み込んだ場合:直ちに医師に連絡すること。
P311 医師に連絡すること。

シルデナフィル 価格 もっと(9)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01CAY10008671
Sildenafil
139755-83-2 10mg ¥8500 2021-03-23 購入
富士フイルム和光純薬株式会社(wako) W01CAY10008671
Sildenafil
139755-83-2 25mg ¥15000 2021-03-23 購入
Sigma-Aldrich Japan S-010 シルデナフィル 溶液 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
Sildenafil solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
139755-83-2 1ml ¥26300 2021-03-23 購入
富士フイルム和光純薬株式会社(wako) W01TRCS435001 シルデナフィル
Sildenafil
139755-83-2 5mg ¥13800 2021-03-23 購入
富士フイルム和光純薬株式会社(wako) W01TRCS435001 シルデナフィル
Sildenafil
139755-83-2 10mg ¥15000 2021-03-23 購入

シルデナフィル 化学特性,用途語,生産方法

用途

シルデナフィル(Sildenafil)は、勃起不全 (ED) 、および肺動脈性肺高血圧症の治療薬である。先発薬としてはファイザーのバイアグラ(Viagra[1]) が商品名(商標)として、肺動脈性高血圧症の治療薬としてはレバチオ(Revatio[2])が商品名として用いられているほか、ファイザーの日本での特許切れにより、各社からの後発医薬品も存在する。

効能

血管拡張薬, 勃起不全治療薬, ホスホジエステラーゼV阻害薬

説明

Sildenafil was launched as Viagra in the US for the treatment of organic orland psychological male erectile dysfunction (ED). Sildenafil can be obtained by functional rearrangement of the corresponding 5-aryl 1,3-dialkyl pyrazolo[4,3- d]pyrimidin-7-one, itself synthesized in a seven-step sequence from a pyrazole- 5-carboxylate. Sildenafil is a potent and selective inhibitor of type V cGMP phosphodiesterases (PDE5) ; IC50 = 3nM on isozymes from human corpus cavernosum tissue. This orally-active therapy is completely new and presents advantages over the classically recommended options such as vacuum constriction devices, drug injection or prosthesis implantation ; for these reasons, this first drug is likely to have a large acceptance fot the treatment of male ED. In experiments with incubated rabbit penile tissue, Sildenafil was shown to cause accumulation of cGMP. By inhibiting the enzyme PDE5, the predominant isozyme in the corpus cavernosum, Sildenafil induces an elevation of levels of second messager cGMP, which is involved in the regulation of vascular tone ; it was suggested that the specific elevation of cGMP due to Sildefanil would mediate an enhancement of nitric oxide-dependent relaxation of corpus cavernosal tissue. Several clinical studies using 10-100 mg Sildenafil have confirmed a good effectiveness and tolerability in healthy males. New trials in women with sexual disfunction have been initiated and positive results could enlarge the potential market of this drug.

化学的特性

White Solid

Originator

Pfizer (UK)

使用

Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor. It is indicated for the treatment of erectile dysfunction (ED). Sildenafil is an orally active selective type 5 cGMP phosphodiesterase inhibitor.

適応症

Sildenafil (Viagra) is a selective inhibitor of PD-5, an enzyme that inactivates cGMP. Vardenifil (Levitra) is a particularly effective inhibitor of PD-5. It has a shorter onset of action and can be used in smaller doses than sildenafil. Other drugs used in the treatment of ED exert their effects through other biochemical pathways, both central and peripheral.

適応症

Sildenafil (Viagra) was developed more than 10 years ago as an antihypertensive and antianginal drug. It proved ineffective in these applications but was shown to affect the smooth muscles of the penis.

定義

ChEBI: A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.

Manufacturing Process

A mixture of 3-n-propylpyrazole-5-carboxylic acid ethyl ester (24.1 g, 0.132 mol) (prepared by the method of Chem. Pharm. Bull., 1984, 32, 1568) and dimethyl sulfate (16.8 g, 0.133 mol) were heated to 90°C for 2.5 h. The mixture was dissolved in dichloromethane and the solution washed with sodium carbonate solution. The organic phase was separated, dried (MgSO4) and evaporated under vacuum to give a solid. Chromatography on silica gel (300 g), eluting with dichloromethane gave the 1-methyl-3-n-propylpyrazole- 5-carboxylic acid ethyl ester as a colourless oil (20.4 g, 79%).
1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester (20.2 g, 0.10 mol) was suspended in 6 N aqueous sodium hydroxide solution (50 ml, 0.30 mol). The mixture was heated to 80°C for 2 h then diluted with water (50 ml) and acidified with concentrated hydrochloric acid (25 ml). Filtration gave the 1- methyl-3-n-propylpyrazole-5-carboxylic acid as pale brown crystals (12.3 g, 71%), melting point 150°-154°C.
1-Methyl-3-n-propylpyrazole-5-carboxylic acid (12.1 g, 0.072 mol) was added portionwise to a mixture of oleum (13 ml) and fuming nitric acid (11 ml), keeping the temperature below 60°C. After the addition, the mixture was heated at 60°C overnight and then cooled to room temperature before being poured onto ice. Filtration of the precipitate gave the 1-methyl-4-nitro-3-npropylpyrazole- 5-carboxylic acid as a white solid (11.5 g, 75%), melting point 124°-127°C.
1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid (11.3 g, 0.053 mol) was added to thionyl chloride (50 ml) and the resulting mixture heated under reflux for 3 h. The reaction mixture was then cooled and excess thionyl chloride removed by evaporation under vacuum. The oily residue was dissolved in acetone (50 ml) and the solution cautiously added to a mixture of ice (50 g) and concentrated aqueous ammonium hydroxide solution (50 ml). The precipitate was collected by filtration to provide the 1-methyl-4-nitro-3-npropylpyrazole- 5-carboxamide as a pale yellow solid (8.77 g, 78%), melting point 141°-143°C.
1-Methyl-4-nito-3-n-propylpyrazole-5-carboxamide (3.45 g, 16.2 mmol) and stannous chloride dihydrate (18.4 g, 81 mmol) were suspended in ethanol and the mixture heated under reflux for 2 h. The resulting solution was cooled to room temperature, basified to pH 9 by the addition of 2 N aqueous sodium hydroxide solution and extracted with dichloromethane (3 x 150 ml). The organic extracts were combined, dried (MgSO4) and evaporated under vacuum. Trituration of the residue with ether gave the 4-amino-1-methyl-3-npropylpyrazole- 5-carboxamide as an off-white solid (2.77 g, 94%), melting point 98°-101°C.
A solution of 2-ethoxybenzoyl chloride (6.1 g, 33.0 mmol) in dichloromethane (50 ml) was added to a stirred solution of 4-amino-1-methyl-3-npropylpyrazole- 5-carboxamide (3.0 g, 16.4 mmol), 4-dimethylaminopyridine (0.02 g, 0.1 64 mmol) and triethylamine (3.34 g, 33.0 mmol) in dichloromethane (50 ml) at 0°C. The resulting mixture was allowed to warm to room temperature and stirred for a further 2 h. The solvent was evaporated under vacuum, the residue dissolved in a 19:1 mixture of dichloromethane and methanol (250 ml), and then the solution washed with 1 N hydrochloric acid (100 ml), dried (MgSO4) and evaporated under vacuum. The crude material was chromatographed on silica gel (200 g), eluting with a 97:3 mixture of dichloromethane and methanol, to give a pink solid; crystallisation from ethyl acetate-hexane gave the 4-(2-ethoxybenzamido)-1-methyl-3-npropylpyrazole- 5-carboxamide as a pale pink solid (2.2 g, 40%), melting point 153°-155°C.
4-(2-Ethoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide (223 g, 0.676 mol) was added portionwise to a solution of sodium hydroxide (54 g, 1.35 mol) and 30% hydrogen peroxide solution (224 ml) in water (2000 ml). Ethanol (700 ml) was added and the resulting mixture heated under reflux for 2.5 h, cooled, then evaporated under vacuum. The resulting solid was treated with 2 N hydrochloric acid (380 ml), with external cooling, and the mixture was extracted with dichloromethane (1 x 700 ml, 3 x 200 ml). The combined organic extracts were washed successively with saturated aqueous sodium carbonate solution (3 x 400 ml) and brine (300 ml), then dried (Na2SO4) and evaporated under vacuum. Chromatography of the residue on silica gel (1000 g), using a methanol in dichloromethane elution gradient (0-1%), followed by trituration of the crude product with ether (300 ml), gave the 5-(2- ethoxyphenyl)-1-methyl-3-n-propyl-l,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin- 7-one as a colourless solid (152.2 g, 72%), melting point 143°-146°C.
5-(2-Ethoxyphenyl)-1-methyl-3-n-propyl-l,6-dihydro-7H-pyrazolo[4,3- d]pyrimidin-7-one (10.0 g, 32.1 mmol) was added portionwise to chlorosulfonic acid (20 ml) at 0°C under a nitrogen atmosphere. After being stirred overnight, the reaction solution was cautiously added to ice-water (150ml) and the aqueous mixture extracted with a 9:1 mixture of dichloromethane and methanol (4 x 100 ml). The combined extracts were dried (Na2SO4) and evaporated under vacuum to give the required 5-(5-chlorosulphonyl-2- ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin- 7-one as a white solid (12.8 g, 97%), melting point 179°-181°C.
4-Methylpiperidine was added to a stirred suspension of 5-(5-chlorosulphonyl- 2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3- d]pyrimidin-7-one in ethanol at room temperature. The resulting mixture was stirred for 4 days before removing the solvent by evaporation under vacuum. The residue was dissolved in a 9:1 mixture of dichloromethane and methanol and the solution washed with saturated aqueous sodium carbonate solution. The aqueous phase was further extracted with dichloromethane-methanol mixtures (3 x 100 ml) and all the organic fractions were combined, dried (MgSO4) and evaporated under vacuum to give a solid. Crystallisation from a mixture of methanol-dimethylformamide gave the 5-[2-ethoxy-5-(4- methylpiperidinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7Hpyrazolo[ 4,3-d]-pyrimidin-7-one as an off-white solid, melting point 187°- 189°C.
After addition of citric acid to the 5-[2-ethoxy-5-(4- methylpiperidinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7Hpyrazolo[ 4,3-d]-pyrimidin-7-one (sildenafil) the it's salt is obtained, namely sildenafil citrate.

brand name

Viagra (Pfizer);Segurex.

Therapeutic Function

Vasodilator

作用機序

Sildenafil is readily absorbed after oral administration and reaches peak plasma levels after about an hour. It undergoes hepatic metabolism and has a terminal half-life of about 4 hours.An initial dose of 50 mg is taken about an hour prior to sexual activity to induce penile erection.

臨床応用

Sildenafil is a selective inhibitor of cGMP-specific PD-5 and therefore inhibits the degradation of cGMP. PD-5, the predominant type in the corpus cavernosum, also is present in other tissues (e.g., lungs, platelets, and eye). The selective inhibition of this enzyme facilitates the release of nitric oxide and smooth muscle relaxation of the corpus cavernosa. Sildenafil enhances erection by augmenting nitric oxide–mediated relaxation pathways. It has been suggested that sildenafil’s mechanism of action is due to cross-talk between cGMP- and cAMPdependent transduction pathways within the cavernous muscles.

副作用

Orally administered sildenafil is an effective and well-tolerated treatment for men with ED, including those with diabetes mellitus. It has also been used for so-called salvage therapy in men who do not respond to intracorporeal injections of other agents. Headache is a common side effect, as are flushing and rhinitis.More serious side effects include definite or suspected myocardial infarctions and cardiac arrest.

酵素阻害剤

Sildenafil is rapidly absorbed and peaks in concentration (127–560 ng/mL) after 0.5 to 2.0 hours, displaying a half-life of 3 to 4 hours for the full therapeutic dose (25–100 mg). It is 96% bound to plasma proteins and is metabolized by the liver CYP3A4. The metabolite N-desmethylsildenafil possesses approximately 50% of the activity of the parent molecule.

代謝

In vitro metabolism studies for sildenafil have shown that the primary metabolite, N-desmethylsildenafil, and the minor metabolite, oxidative opening of the piperazine ring, are mediated by CYP3A4, CYP2C9, CYP2C19, and CYP2D6. The estimated relative contributions to clearance were 79% for CYP3A4, 20% for CYP2C9, and less than 2% for CYP2C19 and CYP2D6. These results demonstrate that CYP3A4 is the primary cytochrome mediating N-demethylation and that drugs inhibiting CYP3A4 likely impair sildenafil biotransformation and clearance. The pharmacokinetics of radiolabeled sildenafil were consistent with rapid absorption, first-pass metabolism, and primarily fecal elimination of N-demethylated metabolites. The absorption of sildenafil following oral administration was rapid (~92%), whereas the oral bioavailability was approximately 38% as a result of first-pass metabolism.

シルデナフィル 上流と下流の製品情報

原材料

準備製品


シルデナフィル 生産企業

Global( 326)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Xi'an ZB Biotech Co.,Ltd
+8618591943808
sales01@xazbbio.com CHINA 1596 58
Anhui Rencheng Technology Co., Ltd
16655163890
admin@ahrencheng.com CHINA 992 58
Hebei Minshang Biotechnology Co.,Ltd
+8613582176207
cathy@hbminshang.cn China 302 58
Hebei Bonster Technology Co.,Limited
+86-13315996897
0086-13315996897 Wendy@bsterltd.com CHINA 998 58
Hebei Binshare New Material Co. Ltd
+8618633865755 +86-86-18633865755
china01@hbbinshare.com CHINA 987 58
Shanxi Lianxu New Material Co., LTD
+8618903404542
Whatsapp: +8618903404542 Wickr me: vevian cathy@lianxu815.com China 526 58
XI'AN TIANGUANGYUAN BIOTECH CO., LTD.
+8618829239519 +86-86-18829239519
188 2923 9519 sales06@tgybio.com China 1228 58
Zhengzhou Hanke Import and export Trade Co. LTD
+8613838064731
sales1@zzybchem.com China 66 58
Shanghai Longyu Biotechnology Co., Ltd.
+8615821988213
+86 15821988213 info@longyupharma.com China 2514 58
Zhejiang Lihui import and export Co. LTD
+8613777515435
li5684158@163.com China 29 58

139755-83-2(シルデナフィル)キーワード:


  • 139755-83-2
  • SILDENAFIL
  • 5-[2-ethoxy-5-(4-methylpiperazin-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazol[4,3d]pyrimidin-7-one
  • 7H-Pyrazolo[4,3-d]pyriMidin-7-one, 5-[2-ethoxy-5-[(4-Methyl -1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-Methyl-3-propyl-
  • Sildenafil solution
  • 5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,4-dihydro-7H-pyrazolo[4,3-d] pyrimidin-7-one
  • 5-[2-Ethoxy-5-[(4-methyl-piperazin-1-yl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one
  • 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
  • 5-[2-ethoxy-5-(4-Methylpiperazine-1-sulfonyl)phenyl]-1-Methyl-3-propyl-1H,6H,7H-pyrazolo[4,3-d]pyriMidin-7-one
  • 1-[[3-(4,7-Dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-Methylpiperazine
  • 5-[2-Ethoxy-5-[(4-Methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-Methyl-3-propyl-7H-pyrazolo[4,3-d]pyriMidin-7-one
  • Revatio
  • UK-92480
  • sildenafil Whatsapp
  • SILDENAFIL CITRATE CAS NO.171599-83-0
  • Sildenafile
  • Manufacturers wholesale 139755-83-2 sildenafil citrate powder CAS NO.139755-83-2
  • Effective Sildenafil Viagra Man Sex Enhancement Powder Sildenafil Citrate CAS 139755-83-2
  • Sildenafil CAS: 139755-83-2
  • Sildenafil h
  • 5-[2-Ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
  • SiIdenafiI
  • 99% high purity Sildenafil CAS No 139755-83-2
  • sildenafil BPC
  • 5-(2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YL-SU LFONYL)PHENYL)-1-METHYL-3-N-PROPYL-6-DIH YDRO-7H-PYRAZOL(4,3-D)PYRIMIDIN-7-ONE
  • Sildefil
  • 5-(2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL)-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE CITRATE
  • 5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsul-fonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
  • viagTa
  • SIDANAFIL
  • 5-[2-Ethoxy-5-(4-methylpiperazin-1-yl-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazol[4.3-d]pyrimidin-7-one
  • シルデナフィル
  • シルデナフィル
  • シルデナフィル 溶液
Copyright 2017 © ChemicalBook. All rights reserved